clinical trial · NCT06411860
A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
Amgen·phase1·completed·n = 32
Basic SciencePlaceboOlpasiranMoxifloxacin
brief summary
The primary objective of the study is: • To assess the effects of a single therapeutic and supratherapeutic dose of olpasiran on the placebo-corrected change from baseline in QT corrected for heart rate (ΔΔQT)/QTc interval in healthy participants.
started
Sep 12, 2024
primary completion
Nov 29, 2024
completion
Dec 11, 2024
last updated
Oct 27, 2025
official title
A Randomized, Placebo- and Positive-controlled, Crossover Study to Assess the Effect of Olpasiran (AMG 890) on QT/QTc Intervals in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol